Search results
For almost 50 years, Retina UK has funded the best science, searching for genes and treatments for everyone living with inherited retinal dystrophies (IRDs). Support the search for treatments for everyone and join our campaign to build the ultimate Gene Team of tomorrow.
The collective partnership of eight of the leading charities in the sight loss sector, known for the last three years as the VI Charity Sector Partnership, has re-launched under a new identity of the ‘Vision Partnership’ with a re-invigorated purpose and new strategic focus.
A round-up of the latest research into inherited retinal conditions - February 2024.
Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.
Charities representing blind and partially sighted people are urging the UK Government to increase benefits in line with inflation rather than wages, when a decision is made at the end of the month.
High quality information on genetic testing and counselling for families affected by inherited sight loss is now available in one place thanks to the launch of an innovative new website, Unlock Genetics.
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
Biotechnology company ProQR has announced encouraging results from its early analysis of the phase 1/2 trial of QR-421a, an innovative approach to treating sight loss caused by mutations in a particular section of the USH2A gene.
Celebrate the life of your loved one, by donating in their memory and help us fund more research and support, now.
Emily Kearney is mum to four boys, aged four to 13, two of whom are living with an inherited sight loss condition.
